2023 FUTURES: Gene Therapy and Gene Editing Sessions
A brief primer on the gene therapy and gene editing approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Alison Mcvie-Wylie, PhD
Vice President, Disease Area Executive, DMD
Vertex Pharmaceutical


Patrick Gonzalez, PhD
Senior Director of Clinical Science Solid Biosciences

Teji Singh, MD
Vice President, Head of Clinical Development Sarepta Therapeutics
